RCA
HRTX icon

Reitz Capital Advisors’s Heron Therapeutics HRTX Stock Holding History

Reitz Capital Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-790
Closed -$12K – 77
2020
Q2 		$12K Buy
+790
New +$13K 0.02% 103

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Reitz Capital Advisors's HRTX Position: Q3 2020 in Review

Reitz Capital Advisors sold out of Heron Therapeutics (HRTX) in Q3 2020, closing a stake of 790 shares — an estimated $12K sold.

Reitz Capital Advisors first reported a position in HRTX in Q2 2020 and held it in 1 quarter. The position peaked at $12K in Q2 2020. 182 funds tracked by Wall St. Rank hold HRTX as of Q3 2020.

  • Reitz Capital Advisors reported no remaining Heron Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Reitz Capital Advisors sold 790 Heron Therapeutics shares in Q3 2020, an estimated $12K.
  • Reitz Capital Advisors first reported a position in Heron Therapeutics in Q2 2020 and held it in 1 quarter.
  • Reitz Capital Advisors's Heron Therapeutics position peaked at $12K in Q2 2020.
  • 182 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2020.

Based on Reitz Capital Advisors's 13F filing for Q3 2020, filed 19 Oct 2020.